Istradefylline
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Istradefylline: From Parkinson’s Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Istradefylline is a selective adenosine A2A receptor antagonist used clinically as adjunct therapy for Parkinson’s disease. The TxGNN model predicts a possible link to Rasmussen Subacute Encephalitis, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on knowledge-graph similarity alone, and the model’s own mechanistic rationale flags the biological direction as questionable.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s disease (per mechanism description; drug is not currently licensed in Taiwan, so no formal approved-indication text is on file) |
| Predicted New Indication | Rasmussen Subacute Encephalitis |
| TxGNN Prediction Score | 99.02% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Taiwan Market Status | Not Marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Istradefylline is a selective adenosine A2A receptor antagonist. Its established clinical mechanism centers on modulating striatal dopamine/adenosine signaling, which underlies its use as an adjunct in Parkinson’s disease.
Rasmussen encephalitis, by contrast, is a chronic, unilateral, T-cell–mediated autoimmune/inflammatory encephalitis — a pathology with no direct overlap with striatal A2A receptor signaling. Adenosine A2A receptors do have anti-inflammatory regulatory roles on immune cells, but this cuts against rather than for the prediction: antagonizing the receptor could theoretically increase T-cell activation and neuroinflammation, the opposite of what would be needed to treat an autoimmune encephalitis.
In short, this candidate is a knowledge-graph similarity output rather than a pharmacologically motivated hypothesis. The evidence pack itself flags the mechanistic link as weak and directionally uncertain, so it should be treated as an exploratory signal only, not a basis for clinical rationale.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Taiwan Market Information
This drug is not currently marketed in Taiwan (0 licenses on file); no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is L5 (model output only), with zero clinical trials, zero literature, and a mechanistic rationale that the model itself identifies as weak and possibly working in the wrong direction. Combined with a Blocking data gap on Taiwan safety/warning information, there is no basis to advance this candidate.
To proceed, the following is needed:
- TFDA (or manufacturer) package insert data on warnings and contraindications (currently a Blocking data gap)
- Detailed, sourced mechanism-of-action data confirming or refuting the A2A-antagonism hypothesis in autoimmune/inflammatory encephalitis
- Preclinical or case-level evidence testing istradefylline (or A2A antagonists generally) in Rasmussen encephalitis or comparable neuroinflammatory models
- Any emerging clinical trial or case-report data before reconsidering evidence level above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.